AbbVie has cultivated a reputation as a premier dividend payer, delivering a current yield of approximately 3.1% and raising its payout for more than 50 consecutive years when counting its tenure at Abbott. Over the past five years alone, the company has increased its dividend at an average annual rate of 7%, while maintaining a conservative payout ratio below 50%. This combination of yield, growth and balance-sheet discipline ensures that investors benefit from both current income and the potential for ongoing increases, with ample room to support future hikes even after absorbing patent expirations on legacy assets.

AbbVie’s future growth prospects are underpinned by an active pipeline of roughly 90 molecules across immunology, oncology, neuroscience and other therapeutic areas. In 2024 the company invested nearly $11 billion in research and development—more than 20% of revenues—to advance late-stage candidates such as a next-generation psoriasis antibody and a novel Parkinson’s disease therapy. These investments have begun to pay off: in the third quarter, overall revenue climbed 9% year-over-year, driven by double-digit growth in immunology (+12%) and neuroscience (+20%).

AbbVie’s core immunosuppressant portfolio, anchored by its flagship monoclonal antibody, continues to produce substantial and predictable cash flows. Even after biosimilar entry pressured legacy pricing, the business segment delivered mid-single-digit revenue growth in the latest quarter thanks to new indications and increased dosing regimens. This reliable performance not only supports ongoing share buybacks and dividend increases but also frees up resources to fund acquisitions and bolt-on licensing deals that further diversify the revenue base.